Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.
|Slideshows|August 20, 2018
Cardiovascular Risk in T2DM Linked to Inflammatory Markers
Author(s)Gregory M. Weiss, MD
Patients with T2DM and proven cardiovascular disease have elevated markers of inflammation and endothelial stress, according to a new study.
Advertisement
Reference: Shore AC, Colhoun HM, Natali A, et al. Use of vascular assessments and novel biomarkers to predict cardiovascular events in type 2 diabetes: The SUMMIT VIP study. Diabetes Care. 2018.
Advertisement
Related to this article
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA's recent approval of Bayer's finerenone in concomitant CKD and T1D.
The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Beta Bionics' new insulin patch pump, expected to be commercialized in Q1 2027.
Advertisement
Advertisement
Trending on HCPLive
1
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
2
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
3
How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care
4
DAPA-TRIO-HF: Dapagliflozin Improves HF Outcomes Regardless of Healthcare Setting
5